Skip to main content
  1. Right Decisions
  2. Neurology pathways - including headache
  3. Back
  4. Headache
  5. 7. Medication overuse guidance
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

7. Medication overuse guidance

Warning

Background

Medication overuse headache (MOH) is defined as headache occurring on 15 or more days per month in a patient with a pre-existing primary headache and developing as a consequence of regular overuse of acute or symptomatic medication for 3 months. Not all patients taking frequent acute medication for the management of primary headache have MOH. MOH can develop in patients taking medication for other painful conditions. 

MOH most commonly occurs as a complication of the management of migraine, although it can occur in any primary headache disorder. It rarely occurs in cluster headache and if it does the patient usually also has migraine.  

Any acute or symptomatic medication taken for the management of primary headache can result in MOH, although the highest risk is with triptans and opioids. 

  • Simple analgesics (Aspirin, NSAIDs, Paracetamol) > 15 days per month 
  • Triptans, opioids and combination analgesics > 10 days per month 

Medication overuse headache: Prevention

When prescribing acute treatment in primary headache patients should be warned about the risk of medication overuse headache. This is particularly important in patients with migraine. In general the use of simple analgesics and triptans should be restricted to 8-10 days per month. The use of combination analgesics and opioids should be avoided. Preventative treatment should be considered early in patients with frequent headache.

In cluster headache, because the headaches are so severe and the risk of MOH very low, patients should be allowed to use up to 2 doses of a triptan per day (subcutaneous sumatriptan or nasal sumatriptan/ zolmatriptan). 

 

Medication overuse headache: Investigation

Before diagnosing MOH it is important to consider other secondary causes of chronic daily headache and investigate appropriately. 

 

Medication overuse headache: Treatment strategies

Explanation

Adequate explanation is the key to managing MOH. The patient should be made aware that frequent use of acute medication “winds up” the migraine process making it more likely to happen and results in chronic headache. MOH is a recognised complication of the management of headache and rationalising/stopping medication can improve headache. Patients should be aware that headache can worsen before it improves (re-bound headache) and that this can last for days/weeks. Headache may still require appropriate management with acute and preventative treatment following medication withdrawal. Resuming frequent acute medication use is likely to result in re-emergence of MOH. 

 

Medication withdrawal

Medication withdrawal is the recommended strategy in patients with MOH. For simple analgesics and triptans abrupt withdrawal is preferable. For combination analgesics (particularly those containing high dose codeine) and opioids gradual withdrawal is recommended. The patient should be warned to expect withdrawal headaches. Other symptoms commonly encountered include: nausea, sleep disturbance and anxiety. Anti-emetics should be considered during the withdrawal phase and patients advised to keep adequately hydrated. Patients overusing triptans can be expected to improve over 7-10 days and those overusing simple analgesics over 2-3 weeks, but improvement can take a few months. For those who cannot manage abrupt withdrawal rationalising acute medication to 2 days per week can be helpful.  

Because medication withdrawal usually results in improvement rather than cessation of headaches adding in or adjusting preventative medication at the same time as initiating withdrawal should be considered. 

 

Preventative treatment 

The effectiveness of most oral preventative treatments is reduced in MOH and if a preventative treatment is started this should be combined with rationalisation of the overused medication. Topiramate, Botulinum Toxin A and CGRP monoclonal antibodies are less likely to be affected by medication overuse. 

 

Referral criteria to secondary care (medication overuse headache)

In patients with Medication Overuse Headache an adequate explanation, trial of medication withdrawal and consideration of starting prophylactic treatment should be undertaken prior to referral into secondary care. 

 

References and further resources

  1. Wakerly, B. Medication Overuse Headache. Practical Neurology. 2019;19:399-403 
  2. SIGN 155 Pharmacological management of migraine – updated March 2023; includes clinician and patient guidelines Pharmacological management of migraine (sign.ac.uk)  
  3. British Association for the Study of Headache (BASH) National Management System 2019; includes clinician and patient portals Headache UK 

 

   gjnh.cfsdpmo@gjnh.scot.nhs.uk

  www.nhscfsd.co.uk

@NHSScotCfSD

Centre for Sustainable Delivery

  Scan the code to visit our website

Editorial Information

Last reviewed: 11/10/2023

Next review date: 01/04/2025

Author(s): Centre for Sustainable Delivery.